vs
Side-by-side financial comparison of Idaho Strategic Resources, Inc. (IDR) and ARS Pharmaceuticals, Inc. (SPRY). Click either name above to swap in a different company.
ARS Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($28.1M vs $14.6M, roughly 1.9× Idaho Strategic Resources, Inc.). Idaho Strategic Resources, Inc. runs the higher net margin — 64.3% vs -147.1%, a 211.4% gap on every dollar of revenue. On growth, Idaho Strategic Resources, Inc. posted the faster year-over-year revenue change (92.0% vs -67.6%).
Idaho Strategic Resources, Inc.IDREarnings & Financial Report
Idaho Strategic Resources, Inc. is a U.S.-based natural resource company focused on the exploration, development, and production of critical and strategic minerals. Primarily operating in Idaho, it targets rare earth elements, gold, silver, and other high-demand minerals, supplying products to the clean energy, defense, and industrial manufacturing sectors across North America.
ARS Pharmaceuticals, Inc. is a late-stage biopharmaceutical firm specializing in the development and commercialization of novel therapies for severe allergic reactions, most notably needle-free epinephrine delivery solutions for anaphylaxis. It primarily operates in the North American market, catering to both pediatric and adult patient groups at risk of life-threatening allergic responses.
IDR vs SPRY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $14.6M | $28.1M |
| Net Profit | $9.4M | $-41.3M |
| Gross Margin | 68.5% | — |
| Operating Margin | 62.4% | -147.6% |
| Net Margin | 64.3% | -147.1% |
| Revenue YoY | 92.0% | -67.6% |
| Net Profit YoY | 220.6% | -182.8% |
| EPS (diluted) | $0.62 | $-0.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $14.6M | $28.1M | ||
| Q3 25 | $11.1M | $32.5M | ||
| Q2 25 | $9.5M | $15.7M | ||
| Q1 25 | $7.3M | $8.0M | ||
| Q4 24 | $7.6M | $86.6M | ||
| Q3 24 | $6.2M | $2.1M | ||
| Q2 24 | $6.1M | $500.0K | ||
| Q1 24 | $5.9M | $0 |
| Q4 25 | $9.4M | $-41.3M | ||
| Q3 25 | $3.0M | $-51.2M | ||
| Q2 25 | $2.8M | $-44.9M | ||
| Q1 25 | $1.6M | $-33.9M | ||
| Q4 24 | $2.9M | $49.9M | ||
| Q3 24 | $1.6M | $-19.1M | ||
| Q2 24 | $2.2M | $-12.5M | ||
| Q1 24 | $2.2M | $-10.3M |
| Q4 25 | 68.5% | — | ||
| Q3 25 | 63.6% | — | ||
| Q2 25 | 57.8% | — | ||
| Q1 25 | 50.8% | — | ||
| Q4 24 | 53.3% | — | ||
| Q3 24 | 48.7% | — | ||
| Q2 24 | 50.2% | — | ||
| Q1 24 | 48.1% | — |
| Q4 25 | 62.4% | -147.6% | ||
| Q3 25 | 23.4% | -163.7% | ||
| Q2 25 | 26.6% | -302.9% | ||
| Q1 25 | 19.3% | -466.3% | ||
| Q4 24 | 36.2% | 54.5% | ||
| Q3 24 | 23.4% | -1051.6% | ||
| Q2 24 | 34.2% | -3068.0% | ||
| Q1 24 | 36.3% | — |
| Q4 25 | 64.3% | -147.1% | ||
| Q3 25 | 26.8% | -157.4% | ||
| Q2 25 | 29.2% | -285.6% | ||
| Q1 25 | 22.1% | -425.7% | ||
| Q4 24 | 38.5% | 57.7% | ||
| Q3 24 | 25.8% | -925.0% | ||
| Q2 24 | 35.2% | -2503.2% | ||
| Q1 24 | 36.8% | — |
| Q4 25 | $0.62 | $-0.41 | ||
| Q3 25 | $0.20 | $-0.52 | ||
| Q2 25 | $0.20 | $-0.46 | ||
| Q1 25 | $0.12 | $-0.35 | ||
| Q4 24 | $0.21 | $0.52 | ||
| Q3 24 | $0.12 | $-0.20 | ||
| Q2 24 | $0.17 | $-0.13 | ||
| Q1 24 | $0.17 | $-0.11 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $245.0M |
| Total DebtLower is stronger | $2.3M | $96.4M |
| Stockholders' EquityBook value | $108.2M | $114.3M |
| Total Assets | $116.2M | $327.7M |
| Debt / EquityLower = less leverage | 0.02× | 0.84× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $245.0M | ||
| Q3 25 | — | $288.2M | ||
| Q2 25 | — | $240.1M | ||
| Q1 25 | — | $275.7M | ||
| Q4 24 | — | $314.0M | ||
| Q3 24 | — | $204.6M | ||
| Q2 24 | $6.3M | $218.7M | ||
| Q1 24 | $5.3M | $223.6M |
| Q4 25 | $2.3M | $96.4M | ||
| Q3 25 | $3.0M | $96.2M | ||
| Q2 25 | $3.3M | — | ||
| Q1 25 | $3.7M | — | ||
| Q4 24 | $1.7M | $0 | ||
| Q3 24 | $2.9M | — | ||
| Q2 24 | $2.7M | — | ||
| Q1 24 | $3.3M | — |
| Q4 25 | $108.2M | $114.3M | ||
| Q3 25 | $74.3M | $147.7M | ||
| Q2 25 | $49.3M | $192.3M | ||
| Q1 25 | $39.8M | $229.0M | ||
| Q4 24 | $37.7M | $256.8M | ||
| Q3 24 | $33.1M | $201.0M | ||
| Q2 24 | $25.4M | $215.2M | ||
| Q1 24 | $21.6M | $223.9M |
| Q4 25 | $116.2M | $327.7M | ||
| Q3 25 | $83.1M | $372.8M | ||
| Q2 25 | $57.7M | $313.5M | ||
| Q1 25 | $48.1M | $327.3M | ||
| Q4 24 | $44.0M | $351.2M | ||
| Q3 24 | $40.8M | $217.6M | ||
| Q2 24 | $32.2M | $222.0M | ||
| Q1 24 | $28.7M | $227.6M |
| Q4 25 | 0.02× | 0.84× | ||
| Q3 25 | 0.04× | 0.65× | ||
| Q2 25 | 0.07× | — | ||
| Q1 25 | 0.09× | — | ||
| Q4 24 | 0.05× | 0.00× | ||
| Q3 24 | 0.09× | — | ||
| Q2 24 | 0.11× | — | ||
| Q1 24 | 0.15× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $10.7M | $-43.5M |
| Free Cash FlowOCF − Capex | $8.2M | — |
| FCF MarginFCF / Revenue | 56.0% | — |
| Capex IntensityCapex / Revenue | 17.7% | 0.0% |
| Cash ConversionOCF / Net Profit | 1.15× | — |
| TTM Free Cash FlowTrailing 4 quarters | $12.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $10.7M | $-43.5M | ||
| Q3 25 | $2.4M | $-47.0M | ||
| Q2 25 | $3.5M | $-39.6M | ||
| Q1 25 | $2.4M | $-40.7M | ||
| Q4 24 | $3.2M | $42.0M | ||
| Q3 24 | $2.5M | $-14.5M | ||
| Q2 24 | $2.6M | $-7.3M | ||
| Q1 24 | $2.6M | $-6.7M |
| Q4 25 | $8.2M | — | ||
| Q3 25 | $709.8K | $-47.2M | ||
| Q2 25 | $2.5M | $-39.6M | ||
| Q1 25 | $1.0M | $-40.8M | ||
| Q4 24 | $2.1M | $41.7M | ||
| Q3 24 | $1.9M | $-14.6M | ||
| Q2 24 | $2.4M | $-7.3M | ||
| Q1 24 | $2.3M | $-6.8M |
| Q4 25 | 56.0% | — | ||
| Q3 25 | 6.4% | -145.4% | ||
| Q2 25 | 26.5% | -252.2% | ||
| Q1 25 | 13.8% | -512.1% | ||
| Q4 24 | 28.0% | 48.2% | ||
| Q3 24 | 30.4% | -706.3% | ||
| Q2 24 | 38.7% | -1463.4% | ||
| Q1 24 | 38.3% | — |
| Q4 25 | 17.7% | 0.0% | ||
| Q3 25 | 15.3% | 0.6% | ||
| Q2 25 | 10.8% | 0.3% | ||
| Q1 25 | 19.4% | 1.1% | ||
| Q4 24 | 13.6% | 0.3% | ||
| Q3 24 | 9.8% | 6.8% | ||
| Q2 24 | 4.3% | 7.6% | ||
| Q1 24 | 5.5% | — |
| Q4 25 | 1.15× | — | ||
| Q3 25 | 0.81× | — | ||
| Q2 25 | 1.28× | — | ||
| Q1 25 | 1.50× | — | ||
| Q4 24 | 1.08× | 0.84× | ||
| Q3 24 | 1.56× | — | ||
| Q2 24 | 1.22× | — | ||
| Q1 24 | 1.19× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IDR
Segment breakdown not available.
SPRY
| Products | $20.3M | 72% |
| Other | $7.8M | 28% |
